Ardelyx Inc
Research Ardelyx Inc (ARDX) on Bullrun: market cap USD 1.29B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARDX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.29B
- Financial periodFY2025
- RevenueUSD 407.32M
- Revenue growth22.1%
- Net income-USD 62.00M
- Free cash flow-USD 43.98M
- Gross margin90.3%
Valuation Snapshot
latest market cap is USD 1.29B.
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Frequently asked questions
What is Ardelyx Inc's market cap?
Ardelyx Inc's market capitalization is USD 1.29B.
What does Ardelyx Inc do?
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation;